RIGL

Rigel Pharmaceuticals

44.46

Nov 13 • 3:59 PM ET -1.23 (-2.69%)

44.46

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: SNDX AGIO GERN KURA AAPG VSTM INCY SNY DMRA ARGX

| Held by: AVUV VTI XBI IWM VXF IWN IBB VTWO SCHA BSVO

Scroll to Statements

Index	RUT
Market Cap	837.18M
Enterprise Value	745.66M
Income	307.19M
Sales	288.21M
Book/sh	23.70
Cash/sh	5.27
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	174
IPO	Nov 29, 2000

P/E	2.87
Forward P/E	9.99
PEG	-
P/S	2.90
P/B	1.88
P/C	8.43
P/FCF	9.31
EV/EBITDA	9.37
EV/Sales	2.59
Quick Ratio	2.19
Current Ratio	2.39
Debt/Eq	0.02
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	15.51
EPS next Y	4.45
EPS next Q	1.05
EPS this Y	-83.23%
EPS next Y	36.23%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	34.76% 22.06%
EPS Y/Y TTM	165.65%
Sales Y/Y TTM	2.18%
EPS Q/Q	-55.71%
Sales Q/Q	16.45%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-23.78% 1.12%

Insider Own	3.32%
Insider Trans	-0.79%
Inst Own	89.62%
Inst Trans	-7.15%
ROA	80.16%
ROE	109.18%
ROIC	69.02%
Gross Margin	89.64%
Oper. Margin	26.28%
Profit Margin	106.59%
SMA20	-6.53%
SMA50	-6.29%
SMA200	18.29%
Trades

Shs Outstand	18.78M
Shs Float	18.20M
Short Float	13.93%
Short Ratio	9.79
Short Interest	2.54M
52W High	52.60 -15.48%
52W Low	24.95 78.20%
Volatility	5.18% 4.94%
ATR (14)	2.53
RSI (14)	44.14
Beta	1.25
Rel Volume	0.58
Avg Volume	259.13K
Volume	151,410

Perf Week	12.13%
Perf Month	-5.90%
Perf Quarter	4.73%
Perf Half Y	53.26%
Perf YTD	3.81%
Perf Year	11.48%
Perf 3Y	454.99%
Perf 5Y	39.81%
Perf 10Y	38.94%
Recom	1.80
Target Price	64.40
Prev Close	45.69
Price	44.46
Change %	-2.69%

Consensus

Buy

Avg. Price Target

$64.40

Implied Upside

+44.8%

Analysts8incl. previous ratings

Rating Distribution3 Buy · 5 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 05, 2025	Upgrade	JJefferies	Hold → Buy	$42	-5.5%
Apr 03, 2023	Resumed	PPiper Sandler	Neutral	$2	-95.5%
Jun 09, 2022	Downgrade	CCitigroup	Buy → Neutral
Jun 08, 2022	Downgrade	PPiper Sandler	Overweight → Neutral	$7 → $1	-97.8%
Jun 08, 2022	Downgrade	CCantor Fitzgerald	Overweight → Neutral	$6 → $1	-97.8%
Mar 23, 2022	Initiated	RB. Riley Securities	Neutral	$4	-91.0%
Nov 09, 2020	Downgrade	JJP Morgan	Overweight → Neutral
Nov 15, 2019	Resumed	CCantor Fitzgerald	Overweight	$7 → $5	-88.8%
Sep 26, 2019	Resumed	JJP Morgan	Overweight	$7	-84.3%
Mar 01, 2019	Reiterated	CCantor Fitzgerald	Overweight	$9 → $7	-84.3%
Aug 27, 2018	Initiated	CCitigroup	Buy	$8.50	-80.9%
May 02, 2018	Reiterated	CCantor Fitzgerald	Overweight	$6 → $9	-79.8%
Dec 21, 2017	Resumed	PPiper Jaffray	Overweight	$6	-86.5%
Dec 15, 2017	Initiated	CCantor Fitzgerald	Overweight	$6	-86.5%
Nov 06, 2017	Resumed	HH.C. Wainwright	Buy	$7	-84.3%
Mar 09, 2017	Reiterated	HH.C. Wainwright	Buy	$6 → $5	-88.8%
Aug 31, 2016	Reiterated	HH.C. Wainwright	Buy	$6 → $7	-84.3%
Aug 30, 2016	Reiterated	PPiper Jaffray	Overweight	$10 → $11	-75.3%
Jul 13, 2016	Initiated	HH.C. Wainwright	Buy	$6	-86.5%
Jun 13, 2016	Initiated	PPiper Jaffray	Overweight

Nov-10-26 08:05AM	Rigel to Present at the Jefferies Global Healthcare Conference in London (PR Newswire)
Nov-05-26 09:02PM	Rigel Misses On EPS As VEPPANU Launch Spending Compresses Margins, While TAVALISSE Slowdown Clouds A Strong Debut (Earnings Whispers) -10.88% -13.26%
06:03PM	Rigel: Q3 Earnings Snapshot (Associated Press)
04:01PM	Rigel Reports Third Quarter 2026 Financial Results (PR Newswire)
Nov-04-26 09:15AM	Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
12:24PM	Loading…
Oct-29-26 12:24PM	Rigel's First Vepinu Quarter Tests Whether Its Breast Cancer Bet Can Offset Slowing Base Sales (Earnings Whispers)
08:05AM	Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results (PR Newswire)
Oct-19-26 08:05AM	Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 (PR Newswire)
Oct-15-26 05:30AM	Big Pharma Is Pouring Billions Into a New Class of 'Protein Degrader' Drugs (The Wall Street Journal)
Oct-02-26 08:05AM	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-02-26 08:05AM	Rigel to Participate in Upcoming September Investor Conferences (PR Newswire)
Aug-14-26 05:28AM	Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers (BioPharma Dive)
Aug-13-26 08:05AM	Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer (PR Newswire)
Aug-04-26 04:08PM	Rigel: Q2 Earnings Snapshot (Associated Press)
04:01PM	Rigel Reports Second Quarter 2026 Financial Results (PR Newswire)
08:05AM	Loading…
Jul-28-26 08:05AM	Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results (PR Newswire)
Jul-07-26 08:05AM	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) +5.73%
Jul-01-26 08:05AM	Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer (PR Newswire)
Jun-16-26 04:01PM	Rigel Announces Closing of Licensing Agreement for VEPPANU (vepdegestrant) (PR Newswire)
May-27-26 08:05AM	Rigel to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-21-26 05:17PM	Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress (PR Newswire)
May-14-26 08:05AM	Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference (PR Newswire)
May-12-26 08:05AM	Arvinas, Pfizer find new partner for Protac breast cancer drug (BioPharma Dive) +12.10%
07:00AM	Rigel Enters Exclusive Global Licensing Agreement for VEPPANU (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer (PR Newswire)
May-05-26 04:36PM	Rigel: Q1 Earnings Snapshot (Associated Press) -5.06%
04:01PM	Rigel Reports First Quarter 2026 Financial Results (PR Newswire)
Apr-28-26 08:05AM	Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results (PR Newswire)
Apr-07-26 08:05AM	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) +5.01%
Mar-31-26 08:05AM	Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology (PR Newswire) +5.13%
Mar-04-26 12:02AM	Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Highlights: Record Net Income and ... (GuruFocus.com) -10.27%
06:02PM	Loading…
Mar-03-26 06:02PM	Rigel Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
05:15PM	Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates (Zacks)
04:18PM	Rigel: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (PR Newswire)
10:00AM	Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan (Zacks)
Feb-27-26 08:32AM	Implied Volatility Surging for Rigel Pharmaceuticals Stock Options (Zacks)
Feb-26-26 10:00AM	Earnings Preview: Profound Medical (PROF) Q4 Earnings Expected to Decline (Zacks)
Feb-25-26 08:05PM	Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-24-26 10:00AM	Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy? (Zacks)
09:02AM	IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential? (Zacks)
08:05AM	Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update (PR Newswire)
Feb-18-26 08:12AM	Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026? (Zacks)
Feb-16-26 08:59AM	RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? (Zacks)
Feb-03-26 08:05AM	Rigel Appoints Michael P. Miller to the Board of Directors (PR Newswire)
Jan-28-26 11:24AM	FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? (Zacks) -5.37%
Jan-16-26 10:26AM	Rigel Pharmaceuticals, Inc. (RIGL) Releases Preliminary Results for Q4 2025 (Insider Monkey)
08:55AM	Profound Medical (PROF) Soars 9.5%: Is Further Upside Left in the Stock? (Zacks)
Jan-12-26 08:05AM	Rigel Provides Business Update and 2026 Outlook (PR Newswire)
Jan-09-26 08:05AM	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -8.22%
Jan-08-26 12:21PM	CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois (Zacks) -5.38%
09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
Jan-07-26 12:31PM	Select Medical Expands Rehab Footprint Through Vibra Healthcare JV (Zacks) +8.66%
08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
08:05AM	Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-06-26 10:00AM	Best Momentum Stocks to Buy for January 6th (Zacks) +5.07%
05:33AM	New Strong Buy Stocks for January 6th (Zacks)
Dec-07-25 09:30AM	Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition (PR Newswire)
Dec-05-25 12:00PM	Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy? (Zacks)
Dec-03-25 04:00PM	AppLovin Stock Rides Swarm Of Setups Beyond Just Mining, Medical Names (Investor's Business Daily) +6.30%
09:40AM	Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock? (Zacks)
Nov-27-25 09:15AM	Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue? (Zacks)
Nov-26-25 08:05AM	Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
Nov-17-25 01:38PM	Eli Lilly Partner And Cancer Treatment Maker Nears Buy Point (Investor's Business Daily)
08:05AM	Rigel Announces Publication of Final 5-year Data on REZLIDHIA (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology (PR Newswire)
Nov-12-25 08:05AM	Rigel to Present at the Jefferies Global Healthcare Conference in London (PR Newswire) +5.24%
Nov-06-25 12:20PM	Surging Earnings Estimates Signal Upside for Rigel (RIGL) Stock (Zacks)
12:00PM	All You Need to Know About Rigel (RIGL) Rating Upgrade to Strong Buy (Zacks)
Nov-05-25 12:01AM	Rigel Pharmaceuticals Inc (RIGL) Q3 2025 Earnings Call Highlights: Record Revenue and Raised ... (GuruFocus.com) +33.37%
Nov-04-25 05:25PM	Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates (Zacks) -7.41%
04:22PM	Rigel: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Nov-03-25 09:05AM	Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
07:57AM	Rigel Pharmaceuticals Inc (RIGL) Q3 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Oct-31-25 01:53PM	Rigel Gears Up to Report Q3 Earnings: Here's What to Expect (Zacks)
Oct-29-25 08:05AM	Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update (PR Newswire)
Oct-15-25 09:40AM	Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now? (Zacks)
Oct-14-25 09:35AM	After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Rigel (RIGL) (Zacks)
Oct-08-25 08:05AM	Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS (PR Newswire)
Oct-03-25 08:05AM	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-29-25 07:09PM	Voya Strengthens Position in Rigel Pharmaceuticals, Inc. (RIGL) (Insider Monkey)
10:04AM	Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse? (Zacks)
09:40AM	Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock? (Zacks)
Sep-26-25 09:35AM	Rigel (RIGL) Loses 27.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-25-25 11:26AM	RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential? (Zacks) -5.22%
Sep-18-25 11:25AM	Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock? (Zacks)
Sep-17-25 02:27PM	What Does Wall Street Think About Rigel Pharmaceuticals (RIGL)? (Insider Monkey)
Sep-11-25 09:48AM	Can Tavalisse Drive Rigel's Growth Through the Rest of 2025? (Zacks)
Sep-09-25 12:00PM	What Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now? (Zacks) -12.09%
Sep-08-25 02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Sep-05-25 09:09AM	Do Options Traders Know Something About RIGL Stock We Don't? (Zacks)
Sep-03-25 02:02PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily)
Aug-27-25 01:57PM	KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82 (Investor's Business Daily)
Aug-26-25 08:05AM	Rigel to Participate in Upcoming September Investor Conferences (PR Newswire)
Aug-25-25 02:03PM	Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock? (Zacks)
10:15AM	This Darling Pharma Stock Is Hitting New Highs, But the Momentum Could Run Out Soon (Barchart)
09:15AM	Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out? (Zacks)
Aug-22-25 09:04AM	Target Stock Market Leaders Rising In Heavy Volume With This Powerful Screen (Investor's Business Daily)
Aug-20-25 12:45PM	Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU (Zacks) +6.21%
Aug-15-25 09:50AM	SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease (Zacks)
Aug-12-25 09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schorno Dean L	EVP & Chief Financial Officer	Sep 02 '26	Option Exercise	21.72	4,600	99,929	82,962	Sep 03 07:02 PM
Ali-Jackson Kamil	Director	Jun 22 '26	Sale	35.00	2,500	87,500	10,125	Jun 24 04:04 PM
Ali-Jackson Kamil	Director	Jun 22 '26	Proposed Sale	35.00	2,500	87,500		Jun 22 03:12 PM
Schorno Dean L	EVP & Chief Financial Officer	Jun 01 '26	Option Exercise	14.83	3,381	50,139	79,718	Jun 03 06:03 PM
Ali-Jackson Kamil	Director	May 26 '26	Sale	29.17	2,500	72,925	12,625	May 28 04:19 PM
Ali-Jackson Kamil	Director	May 26 '26	Proposed Sale	29.17	2,500	72,925		May 26 10:43 AM
MOOS WALTER H	Director	Feb 20 '26	Option Exercise	24.00	4,000	96,000	16,722	Feb 24 04:58 PM
MOOS WALTER H	Director	Feb 20 '26	Sale	36.36	4,000	145,440	12,722	Feb 24 04:58 PM
MOOS WALTER H	Director	Feb 20 '26	Proposed Sale	36.36	4,000	145,440		Feb 20 01:52 PM
RODRIGUEZ RAUL R	CEO, President	Jan 26 '26	Option Exercise	27.40	80,000	2,192,000	285,243	Feb 04 04:20 PM
Schorno Dean L	EVP & Chief Financial Officer	Dec 22 '25	Option Exercise	21.51	6,500	139,786	64,235	Dec 29 08:06 PM

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

PresidentMr. Raul R. Rodriguez

Executive VP & CFOMr. Dean L. Schorno CPA

Executive VPMr. Raymond J. Furey J.D.

Executive VP & Chief Commercial OfficerMr. David A. Santos

Executive VP & Chief Medical OfficerDr. Alison L. Hannah M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

RIGL

Rigel Pharmaceuticals

Upgrade your Finviz experience

All the Features.
Half the Price.